Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. EXAS
stocks logo

EXAS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
860.75M
+20.65%
0.075
-225.78%
831.95M
+17.71%
0.103
-128.8%
919.47M
+13.36%
0.306
+205.86%
Estimates Revision
The market is revising Upward the revenue expectations for Exact Sciences Corporation (EXAS) for FY2025, with the revenue forecasts being adjusted by 2.35% over the past three months. During the same period, the stock price has changed by 87.94%.
Revenue Estimates for FY2025
Revise Upward
up Image
+2.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+6.07%
In Past 3 Month
Stock Price
Go Up
up Image
+87.94%
In Past 3 Month
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 95.50 USD with a low forecast of 50.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 95.50 USD with a low forecast of 50.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
17 Hold
0 Sell
Hold
Current: 101.130
sliders
Low
50.00
Averages
95.50
High
105.00
Current: 101.130
sliders
Low
50.00
Averages
95.50
High
105.00
Stifel
Buy
to
Hold
downgrade
$80 -> $105
2025-11-28
Reason
Stifel
Price Target
$80 -> $105
2025-11-28
downgrade
Buy
to
Hold
Reason
Stifel downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $80, after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Piper Sandler
David Westenberg
Overweight -> Neutral
downgrade
$105
2025-11-24
Reason
Piper Sandler
David Westenberg
Price Target
$105
2025-11-24
downgrade
Overweight -> Neutral
Reason
Piper Sandler analyst David Westenberg downgraded Exact Sciences (EXAS) to Neutral from Overweight with a $105 price target after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Canaccord
Buy
to
Hold
downgrade
$85 -> $105
2025-11-24
Reason
Canaccord
Price Target
$85 -> $105
2025-11-24
downgrade
Buy
to
Hold
Reason
Canaccord downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $85, after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
TD Cowen
TD Cowen
Buy
to
Hold
downgrade
$105
2025-11-24
Reason
TD Cowen
TD Cowen
Price Target
$105
2025-11-24
downgrade
Buy
to
Hold
Reason
TD Cowen downgraded Exact Sciences (EXAS) to Hold from Buy with a $105 price target after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Benchmark
Buy -> Hold
downgrade
$105
2025-11-24
Reason
Benchmark
Price Target
$105
2025-11-24
downgrade
Buy -> Hold
Reason
Benchmark downgraded Exact Sciences (EXAS) to Hold from Buy after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
Nephron Research
Nephron Research
Buy
to
Hold
downgrade
$105
2025-11-21
Reason
Nephron Research
Nephron Research
Price Target
$105
2025-11-21
downgrade
Buy
to
Hold
Reason
Nephron Research downgraded Exact Sciences (EXAS) to Hold from Buy with a $105 price target after the company announced an agreement to be acquired by Abbott (ABT) for $105 per share.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Exact Sciences Corp (EXAS.O) is 120.08, compared to its 5-year average forward P/E of -55.82. For a more detailed relative valuation and DCF analysis to assess Exact Sciences Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-55.82
Current PE
120.08
Overvalued PE
68.89
Undervalued PE
-180.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
72.25
Undervalued EV/EBITDA
-70.53

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
5.52
Current PS
0.00
Overvalued PS
8.56
Undervalued PS
2.47
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 614.09% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

EXAS News & Events

Events Timeline

(ET)
2025-12-01
03:52:00
Exact Sciences Downgraded to Hold by Stifel After $105 Acquisition Agreement with Abbott
select
2025-11-20 (ET)
2025-11-20
12:01:29
Exact Sciences sees a 17.2% increase.
select
2025-11-20
08:09:19
Abbott anticipates that the acquisition of Exact Sciences will quickly enhance organic sales.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
12-03NASDAQ.COM
Significant ETF Inflows: XBI, EXAS, RVMD, RNA

  • 52-Week Range of XBI: XBI's share price has a 52-week low of $66.66 and a high of $123.47, with the last trade recorded at $120.40.

  • 200-Day Moving Average: The article suggests that comparing the current share price to the 200-day moving average can be a useful technical analysis tool.

  • ETFs Trading Mechanism: Exchange-traded funds (ETFs) function like stocks, where investors buy and sell "units" that can be created or destroyed based on demand.

  • Impact of Inflows and Outflows: Monitoring week-over-week changes in shares outstanding helps identify ETFs with significant inflows or outflows, which can affect the underlying holdings.

[object Object]
Preview
8.0
12-03CNBC
Wolfe: These Affordable Dividend Stocks Offer Strong Payout Growth

  • Dividend Aristocrats as Investment Opportunities: Wolfe Research highlights that dividend aristocrats, companies that have increased dividends for 25 consecutive years, are currently undervalued with a relative PE of ~0.83x compared to the S&P 500 and a dividend yield of ~2.5%.

  • Becton Dickinson's Performance: Becton Dickinson, with a 2.19% dividend yield, has seen a 16% decline year-to-date despite exceeding earnings expectations, while also planning a significant spin-off sale.

  • Abbott Laboratories' Strategic Acquisition: Abbott Laboratories, yielding 1.84% and up 11% this year, is set to acquire Exact Sciences for up to $23 billion, aiming to enhance its cancer diagnostics capabilities despite recent disappointing earnings.

  • General Dynamics' Strong Growth: General Dynamics has gained 27% year-to-date with a 1.81% dividend yield, raising its earnings guidance and reporting strong performance across all segments, particularly in aerospace.

[object Object]
Preview
8.5
12-02Benzinga
Two Health Care Stocks You Might Consider Selling This Month

  • Exact Sciences Corp Acquisition: Abbott Laboratories is set to acquire Exact Sciences for $105 per share, totaling approximately $21 billion, marking the largest deal in the global health-care sector this year. Exact Sciences' stock has surged 51% recently, with an RSI of 89.8.

  • Haemonetics Corp Earnings Report: Haemonetics reported strong second-quarter earnings of $1.27 per share, exceeding expectations, and raised its FY2026 EPS guidance. The stock has increased by 61% over the past month, with an RSI of 89.4.

  • Momentum Indicators: Both Exact Sciences and Haemonetics are considered overbought based on their high RSI values, which indicate strong momentum but may signal potential risks for investors.

  • Market Performance: Despite recent gains, shares of Exact Sciences and Haemonetics experienced slight declines on the latest trading day, closing at $101.20 and $80.96, respectively.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Exact Sciences Corp (EXAS) stock price today?

The current price of EXAS is 101.13 USD — it has decreased -0.12 % in the last trading day.

arrow icon

What is Exact Sciences Corp (EXAS)'s business?

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

arrow icon

What is the price predicton of EXAS Stock?

Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 95.50 USD with a low forecast of 50.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Exact Sciences Corp (EXAS)'s revenue for the last quarter?

Exact Sciences Corp revenue for the last quarter amounts to 850.74M USD, increased 20.05 % YoY.

arrow icon

What is Exact Sciences Corp (EXAS)'s earnings per share (EPS) for the last quarter?

Exact Sciences Corp. EPS for the last quarter amounts to -0.10 USD, decreased -52.38 % YoY.

arrow icon

What changes have occurred in the market's expectations for Exact Sciences Corp (EXAS)'s fundamentals?

The market is revising Upward the revenue expectations for Exact Sciences Corporation (EXAS) for FY2025, with the revenue forecasts being adjusted by 2.35% over the past three months. During the same period, the stock price has changed by 87.94%.
arrow icon

How many employees does Exact Sciences Corp (EXAS). have?

Exact Sciences Corp (EXAS) has 6900 emplpoyees as of December 05 2025.

arrow icon

What is Exact Sciences Corp (EXAS) market cap?

Today EXAS has the market capitalization of 19.19B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free